Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
- Novartis Voluntarily Recalls 720,000 Diovan Tablets due to Insect Contamination
March 9, 2012
- The Earthquake-Hit Regions Today 3: “Inventory”as an Edge, Changes in Risk Management
March 9, 2012
- Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
- Daiichi Sankyo Says Mr Yoshiwaka to Become Espha President
March 8, 2012
- MTPC Enters into Agreement for Joint Research of New Vaccines with Canadian Company
March 8, 2012
- US FDA Does Not Approve Additional Indication of AML for Eisai’s Dacogen
March 8, 2012
- “Absolutely No Intention” of Moving Headquarters from Osaka: President Teshirogi of Shionogi
March 8, 2012
- The Earthquake-Hit Regions Today 2: “Irregular Visits” Still Continue for MRs Faced With “Fukushima”
March 8, 2012
- MTPC, Daiichi Sankyo Form Strategic Alliance to Jointly Market 2 Diabetes Treatments
March 7, 2012
- Use of Aricept Generics Is Likely to Expand to Nursing Homes: Pharmacist Survey
March 7, 2012
- The Earthquake-Hit Regions Today 1: Difficulties in Securing Pharmacists, Need for Long Sustained Support
March 7, 2012
- Price Reduction Rates for 4 Major Generics Manufacturers at 8.9% to 12.2%: Jiho Survey
March 7, 2012
- Takeda US Subsidiary Millennium Begins International PIII Trial on Alisertib
March 7, 2012
- Long-Listed Drugs Account for Over 60% of Eisai’s Sales: Jiho Survey
March 7, 2012
- Worldwide Sales by Biopharmaceutical Contract Manufacturers Down Slightly in 2010 at US$3.4 Billion: Seed Planning
March 7, 2012
- Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…